What's in Max Zeller Soehne AG's pipeline?

Max Zeller Soehne AG has 5 drugs in our index: 4 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Max Zeller Soehne AG's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/max-zeller-soehne-ag.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Max Zeller Soehne AG — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Max Zeller Soehne AG pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
EPOGAM 1000	EPOGAM 1000	marketed
Valerian-Hop Extract	Valerian-Hop Extract	marketed	Herbal combination / botanical sleep aid		Neurology / Sleep Medicine
Desloratadin	Desloratadin	marketed		5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1	Other
Zeller Entspannung film coated tablet	Zeller Entspannung film coated tablet	marketed	Herbal preparation / Phytotherapeutic agent		Neurology / Mental Health / Sleep & Relaxation

Therapeutic area mix

Neurology / Mental Health / Sleep & Relaxation · 1
Neurology / Sleep Medicine · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Max Zeller Soehne AG:

Cite this brief

Drug Landscape (2026). Max Zeller Soehne AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/max-zeller-soehne-ag. Accessed 2026-05-16.